title: Molecular profiling of gliomas: potential therapeutic implications.
abstract: Gliomas are the most common primary malignant brain tumor. Over the last decade, significant advances have been made in the molecular characterization of this tumor group, identifying predictive biomarkers or molecular actionable targets, and paving the way to molecular-based targeted therapies. This personalized therapeutic approach is effective and illustrated in the present review. Among many molecular abnormalities, BRAF mutation and mTOR activation in pilocytic astrocytomas and subependymal giant cell astrocytomas are actionable targets sensitive to vemurafenib and everolimus, respectively. Chromosome arms 1p/19q co-deletion and IDH mutational status are pivotal in driving delivery of early procarbazine, lomustine and vincristine chemotherapy in anaplastic oligodendroglial tumors. Although consensus to assess MGMT promoter methylation is not reached yet, it may be useful in predicting resistance to temozolomide in elderly patients.
authors.affiliation: AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de neurologie 2-Mazarin, Paris, France.
authors.forename: Agusti
authors.initials: A
authors.lastname: Alentorn
authors.forename: Alberto
authors.initials: A
authors.lastname: Duran-Peña
authors.forename: Sandeep C
authors.initials: SC
authors.lastname: Pingle
authors.forename: David E
authors.initials: DE
authors.lastname: Piccioni
authors.forename: Ahmed
authors.initials: A
authors.lastname: Idbaih
authors.forename: Santosh
authors.initials: S
authors.lastname: Kesari
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology; D014408:Biomarkers, Tumor / Q000378:metabolism; D001932:Brain Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D019008:Drug Resistance, Neoplasm; D005910:Glioma / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D006801:Humans; D058990:Molecular Targeted Therapy; D057285:Precision Medicine / Q000379:methods
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor
keywords: genomics; glioblastoma; kinase inhibitors; molecular profiling; targeted therapies